Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine

Menée sur 647 patients atteints d'un cancer du poumon non à petites cellules, d'un cancer du poumon à petites cellules ou d'une tumeur du thymus de stade avancé, cette étude évalue la faisabilité du concept d'essai "basket" pour évaluer l'effiacité de plusieurs thérapies ciblées en fonction de la présence d'anomalies génomiques spécifiques

Résumé en anglais

Since the days of the ancient Greeks, the pathologic hallmarks of malignancy have been reflected in the language of oncology. Hippocrates was the first to use carcinoma—or crab—to describe the familiar invading sweep of tumor cells across tissue planes, and several hundred years later, Galen described the oncos—or swelling—of tumors from which the field of oncology takes its name. However, although the histopathology of malignancy has remained unchanged across several millennia, scientific advances of the modern era have begun to challenge earlier views of oncology, where patients were treated with an exclusive focus on the tissue of origin of a tumor. The translation of next-generation sequencing (NGS) into oncology practice has begun to demonstrate that although the primary site of origin of a tumor matters, so too does its genetic landscape...